metricas
covid
Annals of Hepatology P-23 TEST AND TREAT: PROFILE OF PATIENTS DIAGNOSED WITH HEPATITIS C IN THE PRISO...
Journal Information
Vol. 28. Issue S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(March 2023)
Vol. 28. Issue S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(March 2023)
Full text access
P-23 TEST AND TREAT: PROFILE OF PATIENTS DIAGNOSED WITH HEPATITIS C IN THE PRISON SYSTEM OF PORTO ALEGRE, BRAZIL
Visits
600
Eduardo Emerim1, Viviane De Lima Cezar1, Elenita Majaro Pinto Ferreira2, Ana Francisca Perinazzo Fontoura3, Daniel Conte Herter3, Roslaine Ifran Amaral4, João Nagildo1, Rafael De Oliveira Nogueira5, Cibele Dresch5, Pauline Soares Ferrugem1
1 Tuberculosis Care Coordination, STI, HIV-Aids and Viral Hepatitis, Municipal Health Secretariat, Porto Alegre, Brazil
2 Prison Health Unit CPPA, Superintendence of Penitentiary Services, Porto Alegre, Brazil
3 Prison Health Unit PFMP/PEPOA, Vila Nova Hospital Association, Porto Alegre, Brazil
4 Prison Health Unit IPF, Superintendence of Penitentiary Services, Porto Alegre, Brazil
5 Specialized Assistance Service Santa Marta, Municipal Health Secretariat, Porto Alegre, Brazil
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 28. Issue S1

Abstracts of the 2022 Annual Meeting of the ALEH

More info
Introduction and Objectives

Hepatitis caused by the C virus (HCV) is a public health problem whose greatest challenge is access to diagnosis and treatment. The population deprived of liberty is considered a priority for approaches involving the disease. This study aimed to identify the prevalence of HCV among patients tested in prisons in Porto Alegre, Brazil and describe the diagnosed profile of the patients.

Materials and Methods

A cross-sectional study with a quantitative approach. Through the “test and treat” project, rapid testing for HCV and the treatment of diagnosed cases were carried out, providing specific pharmacotherapy, without face-to-face specialist medical consult, within 30 days in 5 prisons in Porto Alegre.

Results

1272 tests were performed with a prevalence of 2.04% of HCV (table 1).

The "test and treat" also welcomed patients diagnosed at the entrance door of prisons providing treatment for the disease, totaling 44 patients diagnosed in these prisons. With the exception of 3 patients with non-reactive viral load, 24.4% of patients have already completed treatment, 36.6% of patients are currently undergoing treatment, 22% are awaiting test results or a change of antiretroviral regimen for HIV and 17.1 % went free from prison. As for the profile of patients, 81.8% are male. The age group with the highest prevalence of patients is 41 to 50 years old (33.3%). Regarding race/color, 41.9% of patients are black and 58.1% are white. Regarding drug use, 50% of patients reported using or had used injectable, inhaled substances and/or crack. The patient's APRI score was 0.6 (F0-F1) and FIB-4 was 1.28 (F0-F1).

Conclusions

This is an innovative action for the Population Deprived of Liberty, as it is the first time that patients with HCV have been treated in municipal prisons because of the particularities of the prison system.

Funding

This work was supported by an unrestricted grant provided by Gilead Sciences Brazil.

Full text is only available in PDF
Download PDF
Article options
Tools